Long-term safety and efficacy of teriflunomide-Reference-Cited by-同舟云学术

Long-term safety and efficacy of teriflunomide

Published:2016-02-10 Issue:10 Volume:86 Page:920-930
ISSN:0028-3878
Container-title:Neurology
language:en
Short-container-title:Neurology

Author:

O'Connor Paul,Comi Giancarlo,Freedman Mark S.,Miller Aaron E.,Kappos Ludwig,Bouchard Jean-Pierre,Lebrun-Frenay Christine,Mares Jan,Benamor Myriam,Thangavelu Karthinathan,Liang Jinjun,Truffinet Philippe,Lawson Victoria J.,Wolinsky Jerry S.,

Publisher

Ovid Technologies (Wolters Kluwer Health)

Subject

Neurology (clinical)

Reference11 articles.

1. Teriflunomide and Its Mechanism of Action in Multiple Sclerosis

2. A Phase II study of the safety and efficacy of teriflunomide in multiple sclerosis with relapses

3. Randomized Trial of Oral Teriflunomide for Relapsing Multiple Sclerosis

4. Oral teriflunomide for patients with relapsing multiple sclerosis (TOWER): a randomised, double-blind, placebo-controlled, phase 3 trial

5. Teriflunomide versus subcutaneous interferon beta-1a in patients with relapsing multiple sclerosis: a randomised, controlled phase 3 trial

Cited by 118 articles. 订阅此论文施引文献订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献

1. The patient-reported outcomes for the new brand-generic teriflunomide in relapsing-remitting multiple sclerosis;Clinical Neurology and Neurosurgery;2024-11

2. Long‐Term Safety of Teriflunomide in Multiple Sclerosis Patients: Results of Prospective Comparative Studies in Three European Countries;Pharmacoepidemiology and Drug Safety;2024-07

3. Sustained Effectiveness and Safety Over Time of Teriflunomide in Chinese Patients with Relapsing Multiple Sclerosis in the Greater Bay Area of China: Insights from Real-World Data;Neurology and Therapy;2024-05-16

4. Infektionen und Multiple Sklerose;Fortschritte der Neurologie · Psychiatrie;2024-05-08

5. Teriflunomide in pediatric patients with relapsing multiple sclerosis: Open-label extension of TERIKIDS;Multiple Sclerosis Journal;2024-04-15